SABCS 2015: Good News for Patients With HER2-positive Breast Cancer
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Category: AACR
T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal women with early-stage hormone receptor-positive breast...
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...
On Monday, the U.S. Food and Drug Administration (FDA) rounded out an exciting month for the multiple myeloma community...
As lung cancer awareness month drew to a close, the U.S. Food and Drug Administration (FDA) added another therapeutic...
Guest post by Roy S. Herbst, MD, PhD Yale Comprehensive Cancer Center
On Monday, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the immunotherapeutic...
The flurry of decisions from the U.S. Food and Drug Administration (FDA) on investigational anticancer therapeutics continued last week...